High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.

MLA

Perng, Reury-Perng, et al. “High Efficacy of Erlotinib in Taiwanese NSCLC Patients in an Expanded Access Program Study Previously Treated with Chemotherapy.” Lung Cancer (Amsterdam, Netherlands), vol. 62, no. 1, Oct. 2008, pp. 78–84. EBSCOhost, https://doi.org/10.1016/j.lungcan.2008.02.023.

APA

Perng, R.-P., Yang, C.-H., Chen, Y.-M., Chang, G.-C., Lin, M.-C., Hsieh, R.-K., Chu, N.-M., Lai, R.-S., Su, W.-C., Tsao, C.-J., Hsia, T.-C., Chen, H.-C., Chen, C.-H., Huang, M.-S., Wang, J.-L., Ho, M.-L., Chung, C.-Y., Yu, C.-J., Chang, W.-C., … Kao, W.-Y. (2008). High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer (Amsterdam, Netherlands), 62(1), 78–84. https://doi.org/10.1016/j.lungcan.2008.02.023

Chicago

Perng, Reury-Perng, Chih-Hsin Yang, Yuh-Min Chen, Gee-Chen Chang, Meng-Chih Lin, Ruey-Kuen Hsieh, Nei-Min Chu, et al. 2008. “High Efficacy of Erlotinib in Taiwanese NSCLC Patients in an Expanded Access Program Study Previously Treated with Chemotherapy.” Lung Cancer (Amsterdam, Netherlands) 62 (1): 78–84. doi:10.1016/j.lungcan.2008.02.023.